

17 December 2008

Dr Carole Longson
Director
Health Technology Evaluation Centre
National Institute for Health and Clinical Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 6NA



Quarry House
Quarry Hill
Leeds
LS2 7UE

Tel: [REDACTED]

Dear Carole

Patient Access Scheme - sorafenib for the treatment of renal cell carcinoma (RCC)

I am writing to confirm the Department of Health's position on the Patient Access Scheme (PAS) arrangements that have been proposed by Bayer for sorafenib in the treatment of RCC. The Department also notes that Bayer intends to propose a price increase for the medicine.

The Department is content for NICE to consider the scheme proposed by Bayer but any proposal for a price change will be subject to the provisions of the 2009 PPRS.

Yours sincerely

